RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 CALGB/SWOG 80405 Results Provide Treatment Options for mCRC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 17
OP 18
DO 10.1177/155989771414010
UL http://mdc.sagepub.com/content/14/14/17.abstract
AB The results of the CALGB/SWOG Phase 3 trial [NCT00265850; Venook AP et al. J Clin Oncol 2014] reveal similar outcomes with FOLFIRI (folinic acid, 5-fluorouracil, and irinotecan) or FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) chemotherapy combined with cetuximab or bevacizumab as a first-line treatment for select patients with KRAS wild-type metastatic colorectal cancer (mCRC). The similarities mean that patients have treatment choices and can now opt to start treatment with the regimen that they most prefer.